Armin Zebisch

2.9k total citations
57 papers, 1.5k citations indexed

About

Armin Zebisch is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Armin Zebisch has authored 57 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 24 papers in Molecular Biology and 16 papers in Cancer Research. Recurrent topics in Armin Zebisch's work include Acute Myeloid Leukemia Research (24 papers), Cancer Genomics and Diagnostics (11 papers) and Melanoma and MAPK Pathways (10 papers). Armin Zebisch is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), Cancer Genomics and Diagnostics (11 papers) and Melanoma and MAPK Pathways (10 papers). Armin Zebisch collaborates with scholars based in Austria, Germany and United States. Armin Zebisch's co-authors include Heinz Sill, Jakob Troppmair, Walter Kölch, Albert Wölfler, David Matallanas, Alex von Kriegsheim, Marc R. Birtwistle, Jens Rauch, Diego Romano and Andrea Berghold and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Armin Zebisch

55 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Armin Zebisch Austria 19 895 411 331 302 221 57 1.5k
Toril Holien Norway 24 1.0k 1.1× 372 0.9× 331 1.0× 155 0.5× 93 0.4× 47 1.5k
Giovanni Roti Italy 23 823 0.9× 575 1.4× 312 0.9× 159 0.5× 133 0.6× 57 1.5k
Mei Dong China 18 1.2k 1.4× 167 0.4× 539 1.6× 332 1.1× 159 0.7× 36 1.7k
Stephen J. Blakemore United States 17 969 1.1× 184 0.4× 339 1.0× 135 0.4× 201 0.9× 47 1.4k
Claire Fabre France 19 752 0.8× 423 1.0× 444 1.3× 222 0.7× 88 0.4× 43 1.3k
Elie Traer United States 21 1.1k 1.2× 666 1.6× 353 1.1× 252 0.8× 67 0.3× 64 1.8k
Carmen Vicente Spain 19 1.0k 1.1× 429 1.0× 303 0.9× 293 1.0× 136 0.6× 36 1.7k
Helena Jernberg‐Wiklund Sweden 26 1.3k 1.5× 651 1.6× 556 1.7× 255 0.8× 163 0.7× 60 2.0k
Aaron J. Donner United States 15 1.1k 1.3× 655 1.6× 354 1.1× 232 0.8× 65 0.3× 18 2.1k

Countries citing papers authored by Armin Zebisch

Since Specialization
Citations

This map shows the geographic impact of Armin Zebisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Zebisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Zebisch more than expected).

Fields of papers citing papers by Armin Zebisch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armin Zebisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Zebisch. The network helps show where Armin Zebisch may publish in the future.

Co-authorship network of co-authors of Armin Zebisch

This figure shows the co-authorship network connecting the top 25 collaborators of Armin Zebisch. A scholar is included among the top collaborators of Armin Zebisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armin Zebisch. Armin Zebisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sconocchia, Tommaso, et al.. (2025). Engineered cytokine-expressing MSCs support ex vivo culture of human HSPCs and AML cells. Experimental Hematology. 147. 104790–104790.
2.
Herzog, Sereina A., Gerhard Bachmaier, Andrea Berghold, et al.. (2024). Acute myeloid leukemia in the next-generation sequencing era. Wiener klinische Wochenschrift. 137(15-16). 504–516.
3.
Román-Trufero, Mónica, Gavin A. Whitlock, Matthew J. Fuchter, et al.. (2024). Abstract 618: Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemia. Cancer Research. 84(6_Supplement). 618–618. 1 indexed citations
4.
Lind, K., Thomas Eder, Wolfgang Schöll, et al.. (2024). Impact of Mono- and Bi-Allelic TP53 Aberrations on Transformation of Human HSPCs. Blood. 144(Supplement 1). 5631–5631. 1 indexed citations
5.
Reinisch, Andreas, et al.. (2024). Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions. Biomedicines. 12(3). 599–599. 4 indexed citations
6.
Sconocchia, Tommaso, Karl Kashofer, Christine Beham‐Schmid, et al.. (2023). Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia. 37(4). 843–853. 8 indexed citations
7.
Sconocchia, Tommaso, Theresa Benezeder, Magdalena Lang, et al.. (2023). BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis. Leukemia. 37(11). 2292–2296. 4 indexed citations
8.
Ediriwickrema, Asiri, Karl Kashofer, Christine Beham‐Schmid, et al.. (2021). Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells. Blood. 138(Supplement 1). 2160–2160. 1 indexed citations
9.
10.
Hatzl, Stefan, Florian Posch, Eduard Schulz, et al.. (2020). The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. Pathology & Oncology Research. 26(4). 2831–2833. 4 indexed citations
11.
Lim, Clarice X., Bernett Lee, Michaela Beitzinger, et al.. (2020). miR-181a Modulation of ERK-MAPK Signaling Sustains DC-SIGN Expression and Limits Activation of Monocyte-Derived Dendritic Cells. Cell Reports. 30(11). 3793–3805.e5. 16 indexed citations
12.
Hatzl, Stefan, Clarice X. Lim, Herbert Strobl, et al.. (2019). Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica. 105(2). 375–386. 9 indexed citations
13.
Prochazka, Katharina, Gudrun Pregartner, Frank G. Rücker, et al.. (2018). Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 104(3). 516–523. 64 indexed citations
14.
Huemer, Florian, Lukas Weiß, Daniel Neureiter, et al.. (2018). Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener klinische Wochenschrift. 130(3-4). 115–125. 1 indexed citations
15.
Aberer, Felix, Abderrahim Oulhaj, Julia K. Mader, et al.. (2017). Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 23(7). 1186–1192. 18 indexed citations
16.
Hatzl, Stefan, Rotraud Wieser, Martin Pichler, et al.. (2016). Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Research. 76(12). 3644–3654. 39 indexed citations
17.
Matallanas, David, Marc R. Birtwistle, Diego Romano, et al.. (2011). Raf Family Kinases: Old Dogs Have Learned New Tricks. Genes & Cancer. 2(3). 232–260. 288 indexed citations
18.
Shin, Sung‐Young, Oliver Rath, Armin Zebisch, et al.. (2010). Functional Roles of Multiple Feedback Loops in Extracellular Signal-Regulated Kinase and Wnt Signaling Pathways That Regulate Epithelial-Mesenchymal Transition. Cancer Research. 70(17). 6715–6724. 121 indexed citations
19.
Sill, Heinz, Werner Olipitz, Armin Zebisch, Eduard Schulz, & Albert Wölfler. (2010). Therapy‐related myeloid neoplasms: pathobiology and clinical characteristics. British Journal of Pharmacology. 162(4). 792–805. 83 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toril Holien Breakdown of academic impact, for papers by Giovanni Roti Breakdown of academic impact, for papers by Mei Dong Breakdown of academic impact, for papers by Stephen J. Blakemore Breakdown of academic impact, for papers by Claire Fabre Breakdown of academic impact, for papers by Elie Traer Breakdown of academic impact, for papers by Carmen Vicente Breakdown of academic impact, for papers by Helena Jernberg‐Wiklund Breakdown of academic impact, for papers by Aaron J. Donner
Rankless by CCL
2026